No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 26 of the 33 quarters in the window, leaving 7 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 37
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Dyne Therapeutics, Inc. (DYN) stock was $15.40 as of Oct 6, 2026, 4:00 PM EDT, down 0.26% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +18.1% · 3-year avg +17.8%/yr · 5-year avg -0.4%/yr
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.91
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.08
vs Estimate
$-0.75
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DYN | $2.88B | $15.40 | -0.26% | +18.13% | -0.38% | N/A | N/A |
| 2TMDX | $2.77B | $80.28 | -3.27% | -28.15% | +21.77% | N/A | vs DYN |
| 3ARQT | $2.99B | $23.92 | -4.89% | +26.11% | -0.28% | N/A | vs DYN |
| 4ATRC | $2.73B | $53.68 | -4.77% | +61.56% | -4.06% | +13.44% | vs DYN |
| 5ELVN | $3.03B | $42.39 | -6.77% | +130.94% | +24.57% | N/A | vs DYN |
| 6MBX | $2.71B | $56.92 | -2.77% | +248.66% | N/A | N/A | vs DYN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 15 analysts
Average Price Target
$36.00
+133.8% upside
Low
$10.00
Current
$15.40
High
$50.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.13 | $-0.91 | $-0.76 | 11 |
| Quarter ending Dec 2026 | $-1.18 | $-0.91 | $-0.38 | 11 |
| Quarter ending Mar 2027 | $-0.88 | $-0.88 | $-0.88 | 4 |
| Quarter ending Jun 2027 | $-0.86 | $-0.86 | $-0.86 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.98 | $-3.63 | $-3.19 | 14 |
| FY 2027 | $-3.91 | $-3.35 | $-3.01 | 12 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $2.99M | $2.99M | $2.99M | 1 |
| Quarter ending Jun 2027 | $7.56M | $7.56M | $7.56M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $510828.00 | $995727.00 | $2.70M | 9 |
| FY 2027 | $10.92M | $52.80M | $118.71M | 12 |
